Inhibition of Alkbh5 Attenuates Lipopolysaccharide-Induced Lung Injury by Promoting Ccl1 m6A and Treg Recruitment

Abstract

This paper discussed the role of AlkB homologue 5 (Alkbh5) in the progression of lipopolysaccharide (LPS)-induced acute lung injury (ALI). LPS-induced ALI models were established in Alkbh5 knockout (KO) and knock-in (KI) mice. The m6A levels in lung tissues were analysed using m6A dot assays. The lung injury was analysed by determining ALI-related markers and histological staining. Mouse MLE12 cells were exposed to LPS for in vitro experiments, and the influence of Alkbh5 on cell viability, apoptosis and reactive oxygen species (ROS) production was analysed. RNA-seq analysis was performed to analyse gene changes upon Alkbh5 deficiency. Functions of the Alkbh5-C-C motif chemokine ligand 1 (Ccl1) cascade in ALI were further verified using the Alkbh5 antagonist DDO-2728 and a recombinant protein of Ccl1 (mCcl1). Alkbh5 was upregulated in lung tissues following LPS exposure. Alkbh5 knockout in mice mitigated LPS-induced lung injury, as indicated by reduced serum levels of lung injury markers and reduced immune cell infiltration, fibrosis and apoptosis. Conversely, Alkbh5 overexpression in mice resulted in reverse trends. In vitro, Alkbh5 knockdown in MLE12 cells enhanced cell viability while reducing cell apoptosis and ROS production. Mechanistically, Alkbh5 was found to bind to and destabilise Ccl1 mRNA, leading to increased Treg recruitment. Treatment with DDO-2728 or mCcl1 in mice increased Treg infiltration, thus improving lung tissue pathology and reducing lung injury. This study suggests that Alkbh5 is implicated in ALI progression by reducing Ccl1-mediated Treg recruitment, making it a promising target for ALI management.

Keywords

ALI / Alkbh5 / Ccl1 / m6A / sepsis / Tregs

References

[1] M. Cecconi, L. Evans, M. Levy, and A. Rhodes, “Sepsis and Septic Shock,” Lancet 392, no. 10141 (2018): 75-87.

[2] J. E. Gotts and M. A. Matthay, “Sepsis: Pathophysiology and Clinical Management,” BMJ 353 (2016): i1585.

[3] J. Wu, Y. Lan, J. Wu, and K. Zhu, “Sepsis-Induced Acute Lung Injury Is Alleviated by Small Molecules From Dietary Plants via Pyroptosis Modulation,” Journal of Agricultural and Food Chemistry 71, no. 32 (2023): 12153-12166.

[4] J. Luo, T. Xu, and K. Sun, “N6-Methyladenosine RNA Modification in Inflammation: Roles, Mechanisms, and Applications,” Frontiers in Cell and Development Biology 9 (2021): 670711.

[5] F. Zhang, Y. Ran, M. Tahir, Z. Li, J. Wang, and X. Chen, “Regulation of N6-Methyladenosine (m6A) RNA Methylation in Microglia-Mediated Inflammation and Ischemic Stroke,” Frontiers in Cellular Neuroscience 16 (2022): 955222.

[6] J. Pang, T. D. Kuang, X. Y. Yu, et al., “N6-Methyladenosine in Myeloid Cells: A Novel Regulatory Factor for Inflammation-Related Diseases,” Journal of Physiology and Biochemistry 80, no. 2 (2024): 249-260.

[7] W. Huang, T. Q. Chen, K. Fang, Z. C. Zeng, H. Ye, and Y. Q. Chen, “N6-Methyladenosine Methyltransferases: Functions, Regulation, and Clinical Potential,” Journal of Hematology & Oncology 14, no. 1 (2021): 117.

[8] J. Qu, H. Yan, Y. Hou, et al., “RNA Demethylase ALKBH5 in Cancer: From Mechanisms to Therapeutic Potential,” Journal of Hematology & Oncology 15, no. 1 (2022): 8.

[9] X. Jiang, B. Liu, Z. Nie, et al., “The Role of m6A Modification in the Biological Functions and Diseases,” Signal Transduction and Targeted Therapy 6, no. 1 (2021): 74.

[10] J. Wang, J. Wang, Q. Gu, et al., “The Biological Function of m6A Demethylase ALKBH5 and Its Role in Human Disease,” Cancer Cell International 20 (2020): 347.

[11] H. Yin, P. Gu, Y. Xie, et al., “ALKBH5 Mediates Silica Particles-Induced Pulmonary Inflammation Through Increased m(6)A Modification of Slamf7 and Autophagy Dysfunction,” Journal of Hazardous Materials 462 (2024): 132736.

[12] X. Hu, T. Liu, X. Zhuang, L. Wei, and J. Gao, “Inhibition of ALKBH5 Inhibits Inflammation and Excessive Proliferation by Promoting TRIM13 m6A Modifications in Glomerular Mesangial Cells,” Naunyn-Schmiedeberg's Archives of Pharmacology 397, no. 9 (2024): 6779-6789.

[13] C. E. Hughes and R. J. B. Nibbs, “A Guide to Chemokines and Their Receptors,” FEBS Journal 285, no. 16 (2018): 2944-2971.

[14] D. C. Fajgenbaum and C. H. June, “Cytokine Storm,” New England Journal of Medicine 383, no. 23 (2020): 2255-2273.

[15] J. Tauler and J. L. Mulshine, “Lung Cancer and Inflammation: Interaction of Chemokines and hnRNPs,” Current Opinion in Pharmacology 9, no. 4 (2009): 384-388.

[16] J. W. Lee, W. Chun, H. J. Lee, et al., “The Role of Macrophages in the Development of Acute and Chronic Inflammatory Lung Diseases,” Cells 10, no. 4 (2021): 897.

[17] M. Arabpour, A. Saghazadeh, and N. Rezaei, “Anti-Inflammatory and M2 Macrophage Polarization-Promoting Effect of Mesenchymal Stem Cell-Derived Exosomes,” International Immunopharmacology 97 (2021): 107823.

[18] Y. Ohue and H. Nishikawa, “Regulatory T (Treg) Cells in Cancer: Can Treg Cells Be a New Therapeutic Target?,” Cancer Science 110, no. 7 (2019): 2080-2089.

[19] J. Korbecki, K. Kojder, D. Simińska, et al., “CC Chemokines in a Tumor: A Review of Pro-Cancer and Anti-Cancer Properties of the Ligands of Receptors CCR1, CCR2, CCR3, and CCR4,” International Journal of Molecular Sciences 21, no. 21 (2020): 8412.

[20] J. Korbecki, S. Grochans, I. Gutowska, K. Barczak, and I. Baranowska-Bosiacka, “CC Chemokines in a Tumor: A Review of pro-Cancer and Anti-Cancer Properties of Receptors CCR5, CCR6, CCR7, CCR8, CCR9, and CCR10 Ligands,” International Journal of Molecular Sciences 21, no. 20 (2020): 7619.

[21] L. Göschl, C. Scheinecker, and M. Bonelli, “Treg Cells in Autoimmunity: From Identification to Treg-Based Therapies,” Seminars in Immunopathology 41, no. 3 (2019): 301-314.

[22] P. J. Eggenhuizen, B. H. Ng, and J. D. Ooi, “Treg Enhancing Therapies to Treat Autoimmune Diseases,” International Journal of Molecular Sciences 21, no. 19 (2020): 7015.

[23] M. D. Martin, V. P. Badovinac, and T. S. Griffith, “CD4 T Cell Responses and the Sepsis-Induced Immunoparalysis State,” Frontiers in Immunology 11 (2020): 1364.

[24] J. Cabrera-Perez, S. A. Condotta, V. P. Badovinac, and T. S. Griffith, “Impact of Sepsis on CD4 T Cell Immunity,” Journal of Leukocyte Biology 96, no. 5 (2014): 767-777.

[25] N. Karin, “Chemokines and Cancer: New Immune Checkpoints for Cancer Therapy,” Current Opinion in Immunology 51 (2018): 140-145.

[26] J. Korbecki, K. Kojder, K. Barczak, et al., “Hypoxia Alters the Expression of CC Chemokines and CC Chemokine Receptors in a Tumor—A Literature Review,” International Journal of Molecular Sciences 21, no. 16 (2020): 5647.

[27] T. Sun, B. Liu, L. Cai, Y. Zhou, W. Yang, and Y. Li, “Suberanilohydroxamic Acid (SAHA), a HDAC Inhibitor, Suppresses the Effect of Treg Cells by Targeting the c-Myc/CCL1 Pathway in Glioma Stem Cells and Improves PD-L1 Blockade Therapy,” Journal of Neuro-Oncology 168, no. 3 (2024): 457-471.

[28] E. Reijmen, S. De Mey, H. Van Damme, et al., “Transcutaneous Vagal Nerve Stimulation Alone or in Combination With Radiotherapy Stimulates Lung Tumor Infiltrating Lymphocytes but Fails to Suppress Tumor Growth,” Frontiers in Immunology 12 (2021): 772555, https://doi.org/10.3389/fimmu.2021.772555.

[29] G. Ye, J. Li, W. Yu, et al., “ALKBH5 Facilitates CYP1B1 mRNA Degradation via m6A Demethylation to Alleviate MSC Senescence and Osteoarthritis Progression,” Experimental & Molecular Medicine 55, no. 8 (2023): 1743-1756.

[30] H. Liu, H. Lyu, G. Jiang, et al., “ALKBH5-Mediated m6A Demethylation of GLUT4 mRNA Promotes Glycolysis and Resistance to HER2-Targeted Therapy in Breast Cancer,” Cancer Research 82, no. 21 (2022): 3974-3986.

[31] Y. M. Kim, A. Munoz, P. H. Hwang, and K. C. Nadeau, “Migration of Regulatory T Cells Toward Airway Epithelial Cells Is Impaired in Chronic Rhinosinusitis With Nasal Polyposis,” Clinical Immunology 137, no. 1 (2010): 111-121.

[32] J. Lai, S. Yu, X. Li, Q. Wei, and J. Qin, “Mettl14/Igf2bp2-Mediated M6a Modification of Steap1 Aggravates Acute Lung Injury Induced by Sepsis,” Shock 63, no. 2 (2025): 217-225.

[33] W. Wang, H. Wang, and T. Sun, “N(6)-Methyladenosine Modification: Regulatory Mechanisms and Therapeutic Potential in Sepsis,” Biomedicine & Pharmacotherapy 168 (2023): 115719.

[34] D. Wu, C. B. Spencer, L. Ortoga, H. Zhang, and C. Miao, “Histone Lactylation-Regulated METTL3 Promotes Ferroptosis via m6A-Modification on ACSL4 in Sepsis-Associated Lung Injury,” Redox Biology 74 (2024): 103194, https://doi.org/10.1016/j.redox.2024.103194.

[35] J. Ning, Z. Pei, M. Wang, et al., “Site-Specific Atg13 Methylation-Mediated Autophagy Regulates Epithelial Inflammation in PM2.5-Induced Pulmonary Fibrosis,” Journal of Hazardous Materials 457 (2023): 131791.

[36] W. Ji, Y. Huo, Y. Zhang, et al., “Palmatine Inhibits Expression Fat Mass and Obesity Associated Protein (FTO) and Exhibits a Curative Effect in Dextran Sulfate Sodium (DSS)-induced Experimental Colitis,” International Immunopharmacology 132 (2024): 111968.

[37] Y. Liu, R. Song, Z. Lu, et al., “The RNA m(6)A Demethylase ALKBH5 Drives Emergency Granulopoiesis and Neutrophil Mobilization by Upregulating G-CSFR Expression,” Cellular & Molecular Immunology 21, no. 1 (2024): 6-18.

[38] W. L. Yang, A. Sharma, F. Zhang, et al., “Milk Fat Globule Epidermal Growth Factor-Factor 8-Derived Peptide Attenuates Organ Injury and Improves Survival in Sepsis,” Critical Care 19 (2015): 375, https://doi.org/10.1186/s13054-015-1094-3.

[39] H. K. Kwon, C. G. Lee, J. S. So, et al., “Generation of Regulatory Dendritic Cells and CD4+Foxp3+ T Cells by Probiotics Administration Suppresses Immune Disorders,” Proceedings of the National Academy of Sciences of the United States of America 107, no. 5 (2010): 2159-2164.

[40] Y. Liang, J. Wei, J. Shen, et al., “Immunological Pathogenesis and Treatment Progress of Adenovirus Pneumonia in Children,” Italian Journal of Pediatrics 51, no. 1 (2025): 4.

[41] A. Raza, W. Yousaf, R. Giannella, and M. T. Shata, “Th17 Cells: Interactions With Predisposing Factors in the Immunopathogenesis of Inflammatory Bowel Disease,” Expert Review of Clinical Immunology 8, no. 2 (2012): 161-168.

[42] Y. Zhao, J. Chen, L. Kong, Q. Zhang, and Q. Zhu, “The Immune Regulatory Mechanism of Adrenomedullin on Promoting the Proliferation and Differentiation of Dental Pulp Stem Cells,” International Dental Journal 74, no. 6 (2024): 1386-1396.

[43] W. Paganin and S. Signorini, “Inflammatory Biomarkers in Depression: Scoping Review,” BJPsych Open 10, no. 5 (2024): e165.

[44] Y. Chen, L. Wang, M. Liu, et al., “Mechanism of Exosomes From Adipose-Derived Mesenchymal Stem Cells on Sepsis-Induced Acute Lung Injury by Promoting TGF-Beta Secretion in Macrophages,” Surgery 174, no. 5 (2023): 1208-1219.

[45] H. Yang, N. Yin, Q. Gu, et al., “Astragaloside IV Reduces Lung Injury in Lethal Sepsis via Promoting Treg Cells Expansion and Inhibiting Inflammatory Responses,” Pakistan Journal of Pharmaceutical Sciences 36, no. 6 (2023): 1709-1718.

RIGHTS & PERMISSIONS

2025 The Author(s). Cell Proliferation published by Beijing Institute for Stem Cell and Regenerative Medicine and John Wiley & Sons Ltd.